FULC
Fulcrum Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$3.85
+0.26%Price chart
Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
0.3x
Market Cap
$293.74M
MomentumView details →
1D Return
+0.26%
YTD Return
−66.09%
RSI (14)
50.7
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
0.3x
Market Cap
$293.74M
RSI (14)
50.7
MomentumView details →
1D Return
+0.26%
YTD Return
−66.09%
SummaryUpdated Jun 1, 2026
Fulcrum Therapeutics, Inc. (NASDAQ:FULC) is a clinical-stage biopharmaceutical company founded in 2015 and headquartered in Cambridge, Massachusetts. The company went public in July 2019 and focuses on developing treatments for genetically defined rare diseases with high unmet medical need. Fulcrum has evolved from pursuing multiple therapeutic programs to concentrating primarily on <b>pociredir</b> for sickle cell disease, following the discontinuation of its lead program <b>losmapimod</b> for facioscapulohumeral muscular dystrophy (FSHD) in 2024 after Phase 3 trial results failed to meet endpoints.
Similar companies
Latest newsMore news →
Kahn Swick & Foti, LLC is investigating the proposed merger of Fulcrum Therapeutics, Inc. and Slate Medicines, Inc., under which Fulcrum shareholders are expected to own 5.0% of the combined company.16d agoFulcrum Therapeutics and Slate Medicines announced a merger agreement to combine and operate as Slate Medicines, focusing on advancing next-generation migraine therapies.19d agoGreg Tourangeau departed as Vice President, Finance and principal accounting officer of Fulcrum Therapeutics, Inc. by mutual agreement, effective 2026-08-07.26d ago